Conatus Pharmaceuticals Inc. (CNAT)

[Theo]

Conatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meeting

SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (CNAT) announced today that two abstracts – one addressing clinical results with the company’s pan-caspase inhibitor, emricasan, and one addressing preclinical results with the company’s pan-caspase inhibitor, IDN-7314 – have been accepted for oral presentations; and one abstract addressing preclinical results with emricasan has been accepted for a poster presentation at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco November 9-13, 2018. Accepted abstracts were published yesterday on the Hepatology website1.

Abstracts accepted for oral presentations included:

“Multicenter, double-blind, randomized trial of emricasan in subjects post liver transplantation (LT) with recurrent hepatitis C virus (HCV) and liver fibrosis or cirrhosis despite achieving sustained virologic response (SVR),” (abstract #1226, originally accepted as poster, later accepted as oral presentation); and

“Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis,” (abstract #25);

and abstracts accepted for posters included:

“Molecular mechanisms underlying the effects of emricasan in portal hypertension and chronic liver disease: the hepato-sinusoidal cross-talk matters,” (abstract #1344).

Abstract #25 is an AASLD Foundation Abstract Award Recipient and was accepted for presentation in the Presidential Plenary Session on Translational Science and Genomics.

“As we advance toward releasing top-line results over the next 15 months from our three ENCORE Phase 2b clinical trials in patients with nonalcoholic steatohepatitis (NASH), the body of preclinical and clinical data documenting the activity and effects of pan-caspase inhibitors continues to grow,” said Conatus co-founder, President and Chief Executive Officer Steven J. Mento, Ph.D. “Thanks to the work of our principal investigators and our scientific collaborators, we have an ever-deepening understanding of the multiple mechanistic effects of caspase inhibitors on liver structure and function, as well as their disease-modifying potential. We are pleased with the recognition afforded to these latest developments at the upcoming AASLD meeting.”